PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery
Phase 3
Completed
- Conditions
- Pain, Post-surgical
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 360
- Registration Number
- NCT00653354
- Locations
- πΊπΈ
Pfizer Investigational Site, Salt Lake City, Utah, United States
A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-05-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 225
- Registration Number
- NCT00652925
- Locations
- πΈπͺ
Pfizer Investigational Site, Stockholm, Sweden
Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 265
- Registration Number
- NCT00652808
- Locations
- π°π·
Pfizer Investigational Site, Seoul, Korea, Republic of
A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery
Phase 3
Terminated
- Conditions
- Pain
- Interventions
- Drug: Parecoxib/ValdecoxibDrug: Placebo
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 91
- Registration Number
- NCT00651300
- Locations
- π¦πΊ
Pfizer Investigational Site, Perth, Western Australia, Australia
A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea
Phase 3
Terminated
- Conditions
- Diarrhea
- Interventions
- Drug: Calcium CarbonateOther: Calcium carbonate not administeredDrug: nelfinavirDrug: lamivudine + zidovudineDrug: lamivudineDrug: loperamide
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT00650637
- Locations
- πΊπΈ
Pfizer Investigational Site, Houston, Texas, United States
Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554
Phase 1
Completed
- Conditions
- HEPATITIS C (HCV)
- Interventions
- Drug: PF-868554
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2014-01-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00651027
- Locations
- πΊπΈ
Pfizer Investigational Site, Miami, Florida, United States
A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 416
- Registration Number
- NCT00650624
- Locations
- π―π΅
Pfizer Investigational Site, Tokyo, Japan
A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00651287
- Locations
Pfizer Investigational Site
A Multicentre, Double-Blind, Double-Dummy, Randomised Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Diclofenac Sodium in Patients Undergoing Knee Arthroscopy for Anterior Cruciate Ligament (ACL) Reconstruction
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2008-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 328
- Registration Number
- NCT00650598
- Locations
Pfizer Investigational Site
A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7
- Registration Number
- NCT00647907
- Locations
- π¨π³
Pfizer Investigational Site, Taipei, Taiwan
Β© Copyright 2025. All Rights Reserved by MedPath